Affiliate disclosure: Some links in this article are affiliate links. We may earn a commission at no additional cost to you.

Medical disclaimer: This article is for informational purposes only and is not medical advice, diagnosis, or treatment. Not medical advice. Consult a qualified healthcare professional before starting or changing any supplement regimen, particularly if you take medications for blood pressure, blood sugar, or blood clotting.

The comparison most buyers are actually weighing

People who take resveratrol supplements — or who are evaluating whether to start — often encounter pterostilbene described as the “upgraded” form. The core claim is that pterostilbene does what resveratrol does, but gets through the gut wall more reliably. Whether that bioavailability advantage translates to better outcomes in humans is more complicated than most product descriptions acknowledge.

Both compounds belong to the stilbene polyphenol family and share the sirtuin hypothesis: activating SIRT1 and related deacetylases, which appear in preclinical research to be linked to metabolic regulation, cellular stress response, and aging-associated pathways. The preclinical evidence for both compounds is extensive. The human trial record is substantially thinner for both — and thinner still for pterostilbene, which has been studied in fewer and smaller trials than resveratrol.

What the methylation changes, and why it matters for buyers evaluating commercial products, is worth working through before considering the human data.

Japanese knotweed: the commercial source most labels don’t explain

Resveratrol is found in red wine, grapes, peanuts, and several berries. The commercial supplement market, however, draws primarily from a different source: the root of Japanese knotweed (Fallopia japonica, previously classified as Polygonum cuspidatum), which contains trans-resveratrol in concentrations far exceeding those found in grape skin or red wine.

Japanese knotweed is native to East Asia — Japan, China, and Korea. In Japan, it is known as itadori (虎杖), and its root (虎杖根, kojōkon) appears in Kampo formulas used in contexts involving blood stasis and circulation support. The traditional Kampo use predates modern polyphenol chemistry by roughly fifteen centuries and reflects a different pharmacological framework than the SIRT1 hypothesis that drives current supplement marketing. Buyers who assume the traditional Kampo reputation for kojōkon directly supports the sirtuin-activation claims on supplement labels are connecting things the evidence does not directly link.

The commercial reality is that Japanese knotweed produces trans-resveratrol at economically extractable concentrations, and industrial producers — primarily in China — extract and purify the compound to supplement-grade purity. When a supplement label reads “resveratrol from Polygonum cuspidatum extract,” it means knotweed root, regardless of whether the botanical term or the common name appears.

Pterostilbene has a different sourcing profile. Its primary botanical sources are blueberries and cranberries. It is also found in meaningful concentrations in the bark of Pterocarpus marsupium (Indian kino tree), which is where the compound’s name originates. Japanese knotweed contains negligible pterostilbene. Supplement-grade pterostilbene is predominantly produced via chemical synthesis or microbial fermentation processes rather than plant extraction — a distinction relevant for buyers who specifically want plant-derived compounds.

What the methylation actually does

Resveratrol (3,5,4’-trihydroxystilbene) has three hydroxyl groups on its stilbene backbone. Pterostilbene has two of those hydroxyl positions replaced by methoxy groups (–OCH₃ instead of –OH). That is the only structural difference between the two molecules.

The practical consequence is pharmacokinetic. Hydroxyl groups in polyphenols are the primary sites for glucuronidation and sulfation — the conjugation reactions through which the gut wall and liver convert polyphenols into water-soluble forms for urinary excretion. Resveratrol is glucuronidated rapidly, producing a short plasma half-life for the unmodified parent compound. Published human pharmacokinetic studies estimate resveratrol oral bioavailability in the range of approximately 1% as free resveratrol, with peak plasma concentrations appearing briefly before hepatic first-pass metabolism processes most of the absorbed dose.

Pterostilbene’s methoxy groups slow glucuronidation and sulfation, reducing the rate of this clearance pathway. Animal-model pharmacokinetic comparisons report pterostilbene oral bioavailability in the range of 80% — a substantial difference from resveratrol’s figure. Human pharmacokinetic data for pterostilbene is more limited, but the direction of the bioavailability difference is consistent with structural chemistry and replicated across species studied.

Whether higher plasma availability of the parent compound translates to greater biological activity in target tissues is a separate question — one that human intervention trials must answer, and that comparatively few trials have addressed for pterostilbene specifically.

What the research has actually measured

Resveratrol: a longer but still limited trial record

Resveratrol’s entry into supplement culture was accelerated by two influential preclinical findings: Howitz et al. (2003, Nature) identifying resveratrol as a SIRT1 activator in yeast, and Baur et al. (2006, Nature) reporting that high-dose resveratrol was associated with improved metabolic markers and extended survival in obese mice on high-fat diets. These were genuine laboratory contributions. The inference that they would translate cleanly to meaningful human outcomes has been consistently harder to establish in randomized trials.

Key human trials:

Timmers et al. (2011, Cell Metabolism): 150 mg/day resveratrol in 11 obese but non-diabetic men over 30 days. Found metabolic marker changes — lower fasting plasma glucose, reduced inflammation markers, improved indicators of mitochondrial function in muscle biopsy samples. The sample size was small and the study was not powered to measure clinical outcomes.

Poulsen et al. (2013, PLoS ONE): 500 mg/day resveratrol in 24 healthy aging men over 8 weeks. Found no significant improvement in insulin sensitivity or other metabolic markers in this healthy population; some measures trended in unfavorable directions. The contrast with Timmers 2011 illustrates a recurring pattern: metabolic signals observed in obese or metabolically compromised cohorts have not consistently appeared in healthy populations.

A 2019 meta-analysis (Bioscience Reports) covering 21 randomized controlled trials found modest effects on blood pressure and some glycemic markers in subgroups with metabolic syndrome or type 2 diabetes, with no significant effects detected in healthy populations. The overall picture for resveratrol in humans: plausible preclinical mechanisms, real laboratory evidence, population-specific metabolic signals in early-stage research, and no large trials measuring hard clinical endpoints.

Pterostilbene: thinner data, with one notable finding

The human trial base for pterostilbene is substantially smaller than resveratrol’s and spans a narrower range of research questions.

The most frequently cited is Riche DM et al. (2013, PLoS ONE): 80 adults with hypercholesterolemia randomized to 100 mg/day pterostilbene, 250 mg/day pterostilbene, or placebo over 6–8 weeks. The primary endpoint was LDL cholesterol. Results were counterintuitive at the higher dose: the 250 mg/day arm showed a statistically significant increase in LDL compared to placebo. The 100 mg/day arm did not significantly differ from placebo on LDL. The study did report a modest blood pressure reduction in participants who entered with elevated baseline values, appearing at both dose levels.

This paper is worth reading directly rather than through secondary descriptions, which often report only the blood pressure finding and omit the LDL trajectory in the higher-dose arm. For people with existing dyslipidemia, the Riche 2013 finding suggests that high-dose pterostilbene supplementation is not a neutral intervention on lipid markers.

Cognitive research on pterostilbene — primarily in rodent models — has generated preclinical interest, but published randomized controlled trials measuring cognitive outcomes in humans remain limited at the time of writing. Several small human studies in metabolic and lipid contexts exist beyond Riche 2013, but the total participant count across all pterostilbene human research is substantially below the resveratrol literature.

The bioavailability advantage pterostilbene carries over resveratrol does not yet come with a proportional human evidence base. That relationship may change as the research matures; where it currently stands, buyers are taking a position on mechanism and preliminary signals rather than on replicated clinical outcomes.

Side effects and drug interactions

Blood pressure: The Riche 2013 trial found blood pressure reductions in participants with elevated baseline values. For people already managing blood pressure with medication, this signal warrants clinical coordination before combining, rather than representing straightforward benefit.

Anticoagulants and antiplatelet drugs: Stilbene polyphenols affect platelet aggregation in vitro. People taking warfarin, heparin, clopidogrel, or direct oral anticoagulants should discuss supplementation with their prescribing clinician. The clinical magnitude of this interaction at standard supplement doses has not been well-characterized in published drug interaction studies.

Medications affecting blood glucose: Resveratrol has shown glucose-lowering signals in certain human trials. If combining with metformin, insulin, or other hypoglycemic agents, blood glucose monitoring and clinical coordination are appropriate.

CYP450 enzyme inhibition: Pterostilbene has been shown to inhibit certain cytochrome P450 enzymes in vitro, including CYP2C9. Whether this produces clinically relevant drug interactions at commercial supplement doses in humans remains incompletely characterized. Anyone taking prescription medications that are known CYP2C9 substrates — a category that includes several common drugs — should check with a pharmacist before adding pterostilbene.

The LDL signal at higher doses: The Riche 2013 finding with 250 mg/day pterostilbene is reason for people with existing dyslipidemia to monitor lipid panels if experimenting with this category rather than treating the supplement as lipid-neutral.

At doses studied in short-term trials, both resveratrol and pterostilbene appear generally tolerated. Headache and gastrointestinal discomfort — nausea, loose stools — are the most commonly reported adverse effects across the published trial record.

Three entry points in this category

Trans-resveratrol from Polygonum cuspidatum extract (100–500 mg): The form with the largest human trial record, however preliminary. Search trans-resveratrol supplement on Amazon — look for products that specify “trans-resveratrol” on the Supplement Facts panel and disclose the source extract, with a third-party certificate of analysis. NOW Foods, Jarrow Formulas, and Thorne all offer standardized extracts with stated sourcing documentation in this category.

Pterostilbene 50–100 mg: The dose range within the study evidence. The 100 mg dose corresponds to the lower arm in Riche 2013; the 250 mg dose is the one associated with the LDL increase in that study. Search pterostilbene supplement 100mg on Amazon — Jarrow Formulas and Source Naturals are among the more established brands in this specific category. Label transparency on dose and source method is worth checking here given the variation in production routes (plant extraction vs. synthesis).

Combination resveratrol and pterostilbene formulas: Some products stack both compounds on the hypothesis that their pharmacokinetics are complementary — pterostilbene providing more sustained plasma presence, resveratrol contributing the larger preclinical evidence base. Search pterostilbene resveratrol combination supplement on Amazon. The combination hypothesis is mechanistically reasonable; no large human trial has evaluated it against either compound tested alone.

None of these approaches carries established clinical outcomes in humans. The supplement purchase is a position on preliminary and preclinical evidence that may or may not extend to the outcomes popular coverage typically associates with this research area.

Who should not start this without clinical input

• Anyone taking anticoagulant or antiplatelet medications — warfarin, clopidogrel, direct oral anticoagulants, aspirin in therapeutic rather than dietary-supplement doses
• Anyone managing blood sugar with prescription medication (metformin, insulin, sulfonylureas)
• Anyone with dyslipidemia considering pterostilbene doses above 100 mg/day, given the Riche 2013 LDL finding in the 250 mg arm
• Anyone taking medications metabolized through CYP2C9 pathways
• Individuals with a history of hormone-sensitive conditions: resveratrol has demonstrated weak estrogenic activity in some research contexts, a signal worth discussing with an endocrinologist before starting
• Pregnant or breastfeeding individuals: no adequate human safety data exists at supplement doses for either compound
• Anyone already supplementing with other polyphenol or NAD+ pathway compounds at high doses — combined pathway effects are not characterized in published research

For adults without these factors who are evaluating this category: starting at the lower studied dose, monitoring relevant biomarkers (LDL, blood pressure, fasting glucose) at a routine blood draw, and treating this as a long-term hypothesis worth tracking rather than an established intervention provides more actual information than starting at higher doses based on mechanism alone. The Japanese knotweed sourcing context for resveratrol is commercially relevant, and the structural logic of pterostilbene’s methylated form is biochemically coherent. The human trial record for both compounds warrants calibrated attention, not confident expectation.

---

See also: NMN vs. NR: what human trials actually compare on dose, cost, and safety, Astragalus and telomeres: what the astragaloside IV research shows, Ergothioneine’s cytoprotective mechanism versus CoQ10, astaxanthin, and glutathione.